Health Care · Pharmaceutical Preparations

IRON Disc Medicine, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1816736117 filings
Russell 2000

IRON at a glance

Disc Medicine, Inc. (IRON, SEC CIK 1816736) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Disc Medicine, Inc. (IRON) shares worth $776.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Savage William Jacob on November 10, 2026 of 16,035 shares at $85.09 per share.
  • In the last 90 days, IRON insiders reported 0 open-market purchases ($0) and 28 open-market sales ($11.9M) on Form 4, a net sale of $11.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 28 sells
Net −$11.9M
13F holders
28 funds
$776.1M · +1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: clinical-stage biopharma developing novel treatments targeting red blood cell biology, focusing on heme biosynthesis and iron homeostasis pathways
  • New emphasis: submission of NDA for bitopertin in erythropoietic porphyrias (EPP and XLP) with FDA accelerated approval pursuit, ongoing Phase 3 APOLLO trial initiated May 2025
  • Strategic shift: pivot to address FDA complete response letter by generating Phase 3 data for traditional approval; expanding pipeline into myeloproliferative neoplasms with DISC-0974 and DISC-3405
  • Quantitative highlight: approx. 14,000 diagnosed EPP patients US market; Phase 2 trial of DISC-0974 in myelofibrosis anemia showed anemia responses independent of transfusion or JAK inhibitor use
  • Noteworthy fact: received FDA Commissioner’s National Priority Voucher in October 2025 for bitopertin, highlighting regulatory priority for this rare disease therapy

Risk Factors

  • Regulatory risk: Dependency on FDA approval timing and conditions for product candidates impacts commercialization and cost structure
  • Macroeconomic threat: Cash runway extends only to 2029 with $791.2M liquidity; accelerated spending could exhaust funds earlier
  • Supply chain vulnerability: Reliance on third-party CROs and CDMOs for clinical trials and manufacturing with some non-cancellable fees
  • Competitive risk: Potential market disruption from approved therapies competing with bitopertin or other pipeline products
  • Financial risk: Accumulated deficit $510.2M with increasing annual net losses ($212.2M in 2025) and heavy equity reliance for funding

Management Discussion & Analysis

  • No revenue generated; net loss $212.2M in 2025 vs $109.4M in 2024, loss doubled YoY
  • Operating expenses up $106.3M YoY: R&D $170.6M vs $96.7M, SG&A $65.4M vs $33.0M
  • R&D increase driven by bitopertin ($58.8M, +$30.7M), DISC-0974 ($27.6M, +$10.6M); bitopertin lead program
  • Cash and equivalents $791.2M at end 2025; raised $211.0M net proceeds in Oct 2025 equity offering
  • FDA issued CRL for bitopertin NDA in Feb 2026; APOLLO Phase 3 topline data expected Q4 2026 to support resubmission

AI summary of the IRON 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales since inception
  • Net loss $59.5M vs $62.3M YoY, operating expenses $64.2M vs $67.7M
  • Best R&D performer: selcodebart expenses $8.4M, up $1.1M; lowest DISC-3405 at $4.9M, down $7.0M
  • Cash, equivalents and securities $682.8M; October offering added approximately $485.9M net
  • Operating cash outflow $146.6M through nine months; funding expected into 2030, APOLLO supports NDA resubmission by year-end 2026

Risk Factors

  • Newly triggered supply-chain risk: BIOSECURE Act restrictions and China tariffs may disrupt foreign vendors, materials, and clinical trials
  • Most material regulatory update: FDA’s February 2026 CRL rejected bitopertin accelerated approval, requiring APOLLO clinical-benefit evidence
  • Near-term development risk: APOLLO topline results remain subject to FDA review before planned NDA resubmission by end-2026
  • Financial risk: $200.0 million senior secured term loan matures December 1, 2029, with minimum qualified-cash covenant
  • Liquidity risk: Management expects cash, cash equivalents, and marketable securities to fund operations into 2030, based on uncertain assumptions

AI summary of the IRON 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results cover the quarter ended September 30, 2026
  • Corporate update announced alongside the quarterly financial results

Item EX-99.1: Item EX-99.1

  • APOLLO Phase 3 met all primary and secondary endpoints, materially strengthening bitopertin’s path toward EPP approval
  • Bitopertin reduced PPIX 41.4% versus placebo and increased monthly pain-free sunlight exposure by 12.2 hours
Filed Oct 22, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $450.0 million gross equity offering: 6,000,000 shares at $75.00 each, completed October 22, 2026
  • Potential additional 900,000 shares through underwriters’ 30-day option, increasing gross proceeds by $67.5 million

Item 8.01: Other Events

  • Equity offering commenced October 19, 2026, signaling near-term capital raising for operations and development
  • Offering priced October 20, 2026, with terms and proceeds detailed in Exhibits 99.1 and 99.2

Item EX-99.2: Item EX-99.2

  • $450 million gross equity raise at $75.00 per share, strengthening funding for clinical development and commercialization
  • 6,000,000 new shares create dilution for existing shareholders

Item EX-99.1: Item EX-99.1

  • Proposed $350 million underwritten equity offering, signaling substantial funding for Disc Medicine’s development pipeline
  • Underwriters’ 30-day option for an additional $52.5 million, potentially increasing total gross proceeds

Item 2.02: Results of Operations and Financial Condition

  • Preliminary cash, cash equivalents and marketable securities of approximately $682.8 million as of September 30, 2026
  • Liquidity estimate offers investors visibility into near-term funding capacity
Filed Oct 19, 2026Full analysis →

Item 8.01: Other Events

  • APOLLO Phase 3 met all primary and secondary endpoints in 183 EPP/XLP patients, materially de-risking bitopertin’s efficacy profile
  • PPIX reduced 41.4% versus placebo, while monthly pain-free light exposure increased 12.2 hours, both statistically significant

Item EX-99.1: Item EX-99.1

  • APOLLO met both co-primary endpoints, reducing PPIX 41.4% versus placebo and adding 12.2 monthly pain-free light hours
  • All secondary endpoints statistically significant, including fewer phototoxic reactions and greater cumulative light tolerance

Item EX-99.2: Item EX-99.2

  • APOLLO met both co-primary and all secondary endpoints, materially strengthening bitopertin’s case for EPP approval
  • PPIX fell 41.4% versus placebo, while month-six pain-free light exposure increased 12.2 hours

Item 7.01: Regulation FD Disclosure

  • Pivotal Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints
  • Results cover adults and adolescents with erythropoietic protoporphyria, supporting regulatory advancement

AI summaries of IRON 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IRON

Don't miss the next IRON filing

  • Alerts as it files. A push when IRON files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IRON, by share count.
  • Ask anything. An AI agent that reads every IRON filing and answers with sources.

IRON alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Savage William JacobSellNov 10, 2026$85.09
Bitterman KevinSellOct 21, 2026$80.23
Bitterman KevinSellOct 21, 2026$80.23
Bitterman KevinSellOct 21, 2026$80.23
Bitterman KevinSellOct 20, 2026$79.95
Bitterman KevinSellOct 20, 2026$79.95
Bitterman KevinSellOct 20, 2026$79.95
Bitterman KevinSellOct 19, 2026$79.97

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$91.1M-$129.7M-$236.0M
Net Income-$76.4M-$109.4M-$212.2M
Balance Sheet
Total Assets$368.0M$496.8M$806.9M
Equity-$443.6M$739.8M
ROE--24.7%-28.7%
Per Share
EPS$-3.42$-3.96$-6.01
Cash Flow
Operating CF-$73.5M-$93.9M-$180.4M
CapEx$89K$505K$933K

Source: XBRL data in Disc Medicine, Inc. (IRON)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IRON share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IRON shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$776.1M
Q2 202627$1.21B
Q1 202626$1.03B
Q4 202523$1.28B
Q3 202524$931.5M
Q2 202523$604.9M
Q1 202521$386.2M
Q4 202417$318.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IRON filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
8-KOct 22, 2026Analysis-
4Oct 21, 2026--
8-KOct 19, 2026Analysis-
4Sep 16, 2026--
4Sep 15, 2026--
8-KSep 10, 2026Analysis-
4Sep 9, 2026--
4Sep 3, 2026--
4Aug 26, 2026--
4Aug 18, 2026--
4Aug 14, 2026--
4Aug 7, 2026--
10-QJul 30, 2026Analysis
8-KJul 30, 2026Analysis-
4Jul 14, 2026--
4Jul 9, 2026--
8-KJun 30, 2026Analysis-
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 24, 2026--
8-KJun 24, 2026Analysis-
4Jun 23, 2026--

Related Health Care companies

All Health Care →

IRON SEC filings: frequently asked questions

Are IRON insiders buying or selling?

In the last 90 days, Disc Medicine, Inc. (IRON) officers, directors and 10% owners reported no open-market purchases and 28 open-market sales worth $11.9 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IRON stock?

As of September 30, 2026, the largest Disc Medicine, Inc. (IRON) holders among the 13F filers tracked by SignalX were BlackRock ($165.8 million), JPMorgan Chase & Co ($119.5 million), T. Rowe Price Group ($108.4 million), State Street Corp ($92.0 million), Vanguard Capital Management LLC ($90.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in IRON's latest 10-K?

In the 10-K filed February 26, 2026, Disc Medicine, Inc. (IRON) flagged: Regulatory risk: Dependency on FDA approval timing and conditions for product candidates impacts commercialization and cost structure. Macroeconomic threat: Cash runway extends only to 2029 with $791.2M liquidity; accelerated spending could exhaust funds earlier. (AI summary of the Risk Factors section.)

What did IRON report in its latest 8-K?

Disc Medicine, Inc. (IRON) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results cover the quarter ended September 30, 2026.

What are the latest IRON SEC filings?

Disc Medicine, Inc. (IRON) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 12, 2026.

What is IRON's SEC CIK number?

Disc Medicine, Inc. (IRON)'s SEC Central Index Key (CIK) is 1816736. EDGAR lists every IRON filing under that number.

Ask anything about IRON

The research agent reads IRON's filings, financials, insider trades and 13F holders, then answers with sources.